-
Millennium Pharmaceuticals, Inc. v. Aurobindo Pharma USA Inc. et al DC
- 1:19-cv-00471
- D. Del.
- Judge: Colm F. Connolly
+1
- Filed: 03/06/2019
- Closed: 06/10/2020
- Latest Docket Entry: 06/10/2020
- PACER
- Docket updated daily
1
Plaintiff
3
Defendants
1
Accused
Product
2
Patents-in-Suit
463
Days in
Litigation
-
Millennium Pharmaceuticals, Inc. v. Aurobindo Pharma USA Inc. et al DC
- 1:19-cv-00471
- D. Del.
- Judge: Colm F. Connolly
+1
- Filed: 03/06/2019
- Closed: 06/10/2020
- Latest Docket Entry: 06/10/2020
- PACER
- Docket updated daily
Cause of Action
Infringement
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 20 |
The lyophilized compound D-mannitol N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronate.
|
Enforceable and Valid
Entry 55 |
| 31 |
The method of claim 23, wherein the compound of formula (1) is D-mannitol N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronate.
|
Enforceable and Valid
Entry 55 |
| 49 |
A lyophilized cake comprising the compound of claim 20.
|
Enforceable and Valid
Entry 55 |
| 53 |
The method of claim 31 further comprising (c) reconstituting the lyophilized mixture with a pharmaceutically-acceptable carrier.
|
Enforceable and Valid
Entry 55 |
-
Infringement
Aurobindo Pharma Limited
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 3.5 mg/vial bortezomib for injection | US 6,713,446 B2 |
20, 31, 49, 53
|
Infringement
Entry 55
|
Aurobindo Pharma USA Incorporated
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 3.5 mg/vial bortezomib for injection | US 6,713,446 B2 |
20, 31, 49, 53
|
Infringement
Entry 55
|
Eugia Pharma Specialties Limited
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 3.5 mg/vial bortezomib for injection | US 6,713,446 B2 |
20, 31, 49, 53
|
Infringement
Entry 55
|
